Pharmacology/Pharmaceutical Industry
Systematic review: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
29 Oct, 2020 | 08:57h | UTCSummary: PCSK9 inhibitors for prevention of cardiovascular disease – Cochrane Library
Lilly antibody drug fails in a Covid-19 study; others go on
28 Oct, 2020 | 09:10h | UTCLilly antibody drug fails in a Covid-19 study; others go on – CNBC
Perspective: Understanding COVID-19 vaccine efficacy
28 Oct, 2020 | 09:04h | UTCUnderstanding COVID-19 vaccine efficacy – Science
Commentary on Twitter
Having reliable evidence on direct & indirect protection #COVID19 candidate vaccines provide can help plan how to use approved vaccines in a coordinated way, write @mlipsitch & @nataliexdean in this #SciMagPerspective. https://t.co/AjAvrsGLb8 pic.twitter.com/CuKQ94NPE8
— Science Magazine (@ScienceMagazine) October 26, 2020
Latin America’s embrace of an unproven COVID treatment is hindering drug trials
28 Oct, 2020 | 09:01h | UTCLatin America’s embrace of an unproven COVID treatment is hindering drug trials – Nature
Observational Study: Ticagrelor, compared with clopidogrel, is not associated with better outcomes for patients with ACS treated with PCI
28 Oct, 2020 | 08:54h | UTCAssociation of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention – JAMA (free for a limited period)
Editorial: Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes – JAMA (free for a limited period)
Author Interview: Ticagrelor or Clopidogrel for Antiplatelet Therapy After Percutaneous Intervention for Acute Coronary Syndrome? – JAMA
Commentary on Twitter
In @JAMA_current, our article comparing ticagrelor and clopidogrel in patients with an acute coronary syndrome undergoing PCI. A remarkable international collaboration. Bottom line: more expensive med not better. https://t.co/SDAyI7Q1MV pic.twitter.com/RFmmy4qvrW
— Harlan Krumholz (@hmkyale) October 27, 2020
[Abstract Only] Meta-analysis: Complication of vasopressor infusion through peripheral venous catheter
28 Oct, 2020 | 08:49h | UTCComplication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis – The American Journal of Emergency Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Evidence is mounting that vasopressors administered through peripheral IVs are associated w/ minimal complications, especially if safety guidelines are implemented. Check out this recent meta-analysis: https://t.co/2Z0xzGDfRG
Does your ED have a policy on vasopressor PIV admin?
— ASHP Emergency Medicine (@ASHP_EMPharm) October 25, 2020
Review: Prospects for a safe COVID-19 vaccine
27 Oct, 2020 | 09:41h | UTCProspects for a safe COVID-19 vaccine – Science Translational Medicine
FDA Safety Alert: Avoid use of NSAIDs in pregnancy at 20 weeks or later
27 Oct, 2020 | 09:33h | UTCCommentary: FDA Expands Warning on Use of NSAIDs in Pregnancy – NEJM Journal Watch
[Preprint] Randomized trial: Nitazoxanide does not improve symptoms in mild Covid-19 disease
25 Oct, 2020 | 23:46h | UTCEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial – medRxiv
Perspective: The race to make COVID antibody therapies cheaper and more potent
25 Oct, 2020 | 23:43h | UTCThe race to make COVID antibody therapies cheaper and more potent – Nature
[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
25 Oct, 2020 | 23:34h | UTCEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive
Commentary on Twitter (thread – click for more)
‼️Effect of Finerenone on CKD outcomes in T2DM
⚡️Finerenone decreased risk of CKD progression by 18%
⚡️Finerenone decreased CV morbidity & mortality by 14%
Published in @NEJM today https://t.co/XvshpZZCK4@ASNKidney #Kidneywk pic.twitter.com/FOkxnG1enz
— Aisha Shaikh (@aishaikh) October 23, 2020
Narrative systematic review: Benefits of medication charts provided at transitions of care
25 Oct, 2020 | 23:29h | UTC
A global survey of potential acceptance of a COVID-19 vaccine
23 Oct, 2020 | 09:11h | UTCA global survey of potential acceptance of a COVID-19 vaccine – Nature Medicine
Commentary: COVID Vaccine Hesitancy – Science-based Medicine
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Coronavirus vaccine volunteer in Brazil’s AstraZeneca trial dies – but authorities say trial to continue
23 Oct, 2020 | 09:08h | UTCSee also: AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue – Reuters AND Expert reaction to media reports suggesting a person in Brazil who was taking part in the Brazil arm of the Oxford/AstraZeneca vaccine trial has died – Science Media Centre
Randomized trial: Tocilizumab does not improve outcomes for patients hospitalized with Covid-19
22 Oct, 2020 | 09:42h | UTCEfficacy of Tocilizumab in Patients Hospitalized with Covid-19 – New England Journal of Medicine
SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates
22 Oct, 2020 | 09:36h | UTCSARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates – The Lancet
Commentary: The COVID-19 vaccine pipeline – News Medical
Commentary on Twitter
NEW Review—G Poland, I Ovsyannikova & R Kennedy @MayoClinic discuss what is currently known about human humoral & cellular immune responses to SARS-CoV-2 & relate this knowledge to the #COVID19 vaccines currently in phase 3 clinical trials https://t.co/eDkFq4WStA pic.twitter.com/hfw6yjviym
— The Lancet (@TheLancet) October 14, 2020
Will Covid-19 vaccines save lives? Current trials aren’t designed to tell us
22 Oct, 2020 | 09:40h | UTCWill covid-19 vaccines save lives? Current trials aren’t designed to tell us – The BMJ
Commentaries: COVID-19 vaccine trials won’t tell us if the shots save lives, expert notes – CNN AND Coronavirus vaccine trials won’t tell us if they save lives, prevent serious illness or stop transmission – here’s why – The Conversation
Commentary on Twitter
The world is waiting on a vaccine for covid-19 that will reduce the likelihood of getting severely ill and prevent infection. Yet the current phase III trials are not actually set up to prove either, finds Peter Doshi https://t.co/BSb9WiUQXo
— The BMJ (@bmj_latest) October 21, 2020
Meta-analysis: Efficacy and safety of tranexamic acid in acute traumatic brain injury
22 Oct, 2020 | 09:31h | UTC
Commentary on Twitter
Tranexamic acid in acute TBI
➡️ 9 RCTs/14,747 pts
➡️ probably NO effect on mortality or disability
➡️ may decrease hematoma expansion on subsequent imaging (likely of minor importance to pts)
➡️ probably NO increased risk of adverse events#FOAMcc @yourICM https://t.co/sqn80NfNv4 pic.twitter.com/dMf8rYowC2— Intensive Care Medicine (@yourICM) October 21, 2020
Meta-analysis: Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents
22 Oct, 2020 | 09:29h | UTC
Studies offer little hope for Tocilizumab in treating COVID
21 Oct, 2020 | 09:27h | UTCStudies offer little hope for tocilizumab in treating COVID – CIDRAP
See studies: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 – JAMA Internal Medicine AND Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine AND Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine
Commentary: expert reaction to three studies of Tocilizumab to treat COVID patients – Science Media Centre
Related study (preprint): Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Meta-analysis: Evaluating prophylactic heparin in ambulatory patients with solid tumors
22 Oct, 2020 | 09:23h | UTCEvaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis – The Lancet Haematology (free registration required)
Dozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials
21 Oct, 2020 | 09:25h | UTCDozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials – Nature
Commentaries: U.K. Preparing COVID-19 Vaccine Trials That Deliberately Expose Study Subjects – NPR AND UK plan to be first to run human challenge Covid trials – BBC
Covid-19 vaccine protocols reveal that trials are designed to succeed
20 Oct, 2020 | 01:40h | UTCCovid-19 Vaccine Protocols Reveal That Trials Are Designed To Succeed – Forbes
Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?
20 Oct, 2020 | 01:38h | UTC
Commentary on Twitter
Side effect of #COVID19 surge: ignoring well established strategies
➡️ limit ABTs exposure vs resistances: MV/long #ICU stay
➡️ avoid toxicity: antivirals/antibiotics can have severe adverse effects/interactions
➡️ high mortality: improving outcome crucial https://t.co/FN3LtKKlsr pic.twitter.com/7KGbIOH3Uf— Intensive Care Medicine (@yourICM) October 17, 2020